• Wed news: Wegovy sales soar. Trump wins - effect on healthcare remains unclear. Teva Pharma earnings. Lexicon Pharma’s persistence. Moderna’s Bancel steps down as sales chief. See more on our front page

Sotyktu floundering

Quote












I am closing in on a 40% share this month. I don't work Fridays. EVER. But I'll be back at it Monday morning and with any luck, I will have a 40% share if I count equivalents and exclude a few products from the market basket.

LFG!
 




anonymous said:
Same as BMS-came to market for an easy indication. Burnt, and their sales division has a similar, whiny, do nothing dysfunctionality. Sales people and marketing fail. Sorry guys, nothing wrong with these assets. We think you just suck at what you are supposed to be experts at doing.
Click to expand...
I left BMS already but this failure was purely marketing's fault. Everyone in medical knew that there was 0 purpose in targeting top KOLs like Armstrong and others.. the efficacy data is shit compared to injectables. Who tf would ever give up PASI 100 for this mediocre pill? If they were more humble about this drug and didn't make themselves so loud over it being a TYK2 and not a JAK (it's still a JAK), maybe things would've been ok. Not surprised though, BMS has always been full of tards.
 




anonymous said:
I left BMS already but this failure was purely marketing's fault. Everyone in medical knew that there was 0 purpose in targeting top KOLs like Armstrong and others.. the efficacy data is shit compared to injectables. Who tf would ever give up PASI 100 for this mediocre pill? If they were more humble about this drug and didn't make themselves so loud over it being a TYK2 and not a JAK (it's still a JAK), maybe things would've been ok. Not surprised though, BMS has always been full of tards.
Click to expand...
The drug is fine, it works, is safer than the JAKs (cuz in reality, it binds to an unrelated, site and the JAK affinity only come into play at non-clinical exposures). It's problem is that it was not first to market, and clinical went after PSor. That the sales team screwed it up with some of the cringiest marketing in the history of marketing did not help. Sotyktu may not win in the PSA space, but second generation molecules in this space will hold promise for a variety auto immune disorders.
Finally, be it the science, or the market target assumptions, kindly get back to the thread when you have more than an urge to fartiin a public forum.
 




anonymous said:
The drug is fine, it works, is safer than the JAKs (cuz in reality, it binds to an unrelated, site and the JAK affinity only come into play at non-clinical exposures). It's problem is that it was not first to market, and clinical went after PSor. That the sales team screwed it up with some of the cringiest marketing in the history of marketing did not help. Sotyktu may not win in the PSA space, but second generation molecules in this space will hold promise for a variety auto immune disorders.
Finally, be it the science, or the market target assumptions, kindly get back to the thread when you have more than an urge to fartiin a public forum.
Click to expand...
If you think there's any real hope for it in SLE, Sjorgens, etc. any of those disorders you're fooling yourself bud. It's a dead product. The writing is on the wall when the literal scientist who helped develop the molecule leaves your team (Ryan) lmfao. Shit product supported by a dumb company full of leadership that sips the kool-aid and is too afraid to go anywhere else since they're sitting on stock now.
 




anonymous said:
The drug is fine, it works, is safer than the JAKs (cuz in reality, it binds to an unrelated, site and the JAK affinity only come into play at non-clinical exposures). It's problem is that it was not first to market, and clinical went after PSor. That the sales team screwed it up with some of the cringiest marketing in the history of marketing did not help. Sotyktu may not win in the PSA space, but second generation molecules in this space will hold promise for a variety auto immune disorders.
Finally, be it the science, or the market target assumptions, kindly get back to the thread when you have more than an urge to fartiin a public forum.
Click to expand...
Drug sucks and has little potential in SLE, Sjorgens, etc. no matter how much the global teams think they're important at BMS. When the scientist/spokesperson for psoriasis who literally helped discover sotyktu (Ryan) leaves the company, you know shit has hit the fan already.
 




anonymous said:
Drug sucks and has little potential in SLE, Sjorgens, etc. no matter how much the global teams think they're important at BMS. When the scientist/spokesperson for psoriasis who literally helped discover sotyktu (Ryan) leaves the company, you know shit has hit the fan already.
Click to expand...
He left because he couldn't hack it in medical - dealing with customers needs a different set of skills that he doesn't have.
 




anonymous said:
Drug sucks and has little potential in SLE, Sjorgens, etc. no matter how much the global teams think they're important at BMS. When the scientist/spokesperson for psoriasis who literally helped discover sotyktu (Ryan) leaves the company, you know shit has hit the fan already.
Click to expand...
Nah. Thats not why he left, nor any of the others. They after Celgene's catastrophe. Drug is fine.
Going to have trust me on this...
 




anonymous said:
Drug sucks and has little potential in SLE, Sjorgens, etc. no matter how much the global teams think they're important at BMS. When the scientist/spokesperson for psoriasis who literally helped discover sotyktu (Ryan) leaves the company, you know shit has hit the fan already.nope
Click to expand...
Nope. All the inventors left after the Celvene catastrophe. Nothing to do with the drug, whuch is fine.
 




....the scientific leadership of the product left because of management and leadership changes associated with recent, disastrous, management decisions, not because "the drug sucks".
 




....the scientific leadership of the product left because of management and leadership changes associated with recent, disastrous, management decisions, not because "the drug sucks".
 












anonymous said:
Things are really that bad over at Amgen?
Click to expand...
Hard to say. I know two MSLs that are still left at Amgen from the I&I days. Both east coast. Both says it's ok for them, but they focus on internal customers more than actual customers. They do say that their field colleagues are in misery. They say they have an evil sales lead that is hell bent on destroying every molecule of the Celgene culture and is clearly in if only for herself.
 








anonymous said:
....the scientific leadership of the product left because of management and leadership changes associated with recent, disastrous, management decisions, not because "the drug sucks".
Click to expand...
i am sure we will never see a better example of how incompetent leadership can single handily ruin a launch. Will anyone ever be accountable?
 




I love all the posts on LinkedIn from the Sotyktu TEAM saying great things about the GI sales force who were all just laid off. What a joke. For 2+ years the derm team has said they don’t want meetings with us, they are better than us, and now are saying we were great and to please help if you can. Give me a break. Your managers have roles open and they won’t even give us an interview. BMS is a disaster! I should have listened to my old partner who left months ago.
 




anonymous said:
I love all the posts on LinkedIn from the Sotyktu TEAM saying great things about the GI sales force who were all just laid off. What a joke. For 2+ years the derm team has said they don’t want meetings with us, they are better than us, and now are saying we were great and to please help if you can. Give me a break. Your managers have roles open and they won’t even give us an interview. BMS is a disaster! I should have listened to my old partner who left months ago
Click to expand...
No lies detected.
 




Top Bottom
Back
Quote